Castleman disease is a rare disorder of the lymph nodes that causes swollen glands and inflammation. People with Castleman disease may have fatigue, fever, night sweats, weight loss, and enlarged nodes in the neck, armpit, or groin. Symptoms can range from mild to severe, and some forms are chronic while others flare and improve. Treatment often includes medicines that calm the immune system, targeted therapy, steroids, or surgery for a single enlarged node. The outlook varies by subtype, but many people with Castleman disease do well with modern care.
Overview
Castleman diseaseSymptoms
Early symptoms of Castleman disease are often absent, especially with a single enlarged lymph node. When widespread, people may have fever, drenching night sweats, severe tiredness, unintentional weight loss, swollen nodes, belly fullness or swelling, and repeated infections.
Outlook and prognosis
Many living with Castleman disease do well, especially when it’s found early and matched with the right treatment plan. Unicentric disease often improves after surgery, while multicentric types may need ongoing therapy and close follow-up. Relapses can happen, but regular monitoring helps manage flares and prevent complications.
Causes and risk factors
Causes of Castleman disease vary. Multicentric forms are often driven by human herpesvirus‑8; HIV, immunosuppression, and older age raise risk, while autoimmune conditions, chronic inflammation, and certain plasma‑cell disorders can be associated; many cases remain idiopathic.
Genetic influences
Genetics play a limited role in Castleman disease; most cases are not inherited. Variations in immune-related genes may influence risk or how active the disease becomes. In some subtypes, viruses like HHV‑8, not inherited variants, drive the condition.
Diagnosis
Doctors diagnose Castleman disease using symptoms, exam, blood tests, and imaging to find enlarged lymph nodes. A lymph node biopsy confirms the diagnosis of Castleman disease and its subtype. Additional tests may check HHV-8 or HIV.
Treatment and drugs
Treatment for Castleman disease depends on the subtype and how active the disease is. Many respond to targeted therapies that calm the immune system (like siltuximab or tocilizumab), sometimes with steroids, antivirals, or chemotherapy; surgery helps when a single lymph node is involved. Care teams also treat symptoms such as pain, anemia, infections, and swelling, and monitor closely to adjust plans.
Symptoms
Castleman disease can cause swollen lymph nodes and whole‑body inflammation that affects energy, appetite, and temperature control. Early symptoms of Castleman disease can be subtle, such as a firm lump in the neck or underarm, unexplained fatigue, or night sweats. Some people have one enlarged lymph node with few symptoms, while others have many nodes involved along with fever and weight loss. Symptoms vary from person to person and can change over time.
Painless, firm lumps in the neck, underarm, or groin are common. They may stay the same size for months or slowly get larger over time. You might notice small changes at first.
Repeated fevers, chills, and drenching night sweats can occur with Castleman disease. Many also feel flushed or shivery without a known infection.
Ongoing tiredness and low stamina are common and may not improve with rest. What once felt effortless can start to require more energy or focus.
Unintended weight loss and a poor appetite can develop, especially with multicentric disease. Loved ones often notice the changes first.
How people usually first notice Castleman disease?
Many people first notice Castleman disease when swollen lymph nodes appear in the neck, armpit, or groin and don’t go away, sometimes with a feeling of fullness or pressure nearby. Early warning signs can include persistent fatigue, fevers, night sweats, and unintentional weight loss, and some develop skin flushing or a rash, frequent infections, or swelling in the legs or abdomen from fluid buildup. Doctors often first suspect it after routine exams or imaging pick up enlarged lymph nodes and blood tests show inflammation or anemia, prompting a biopsy to confirm the diagnosis; these are common first signs of Castleman disease.
Types of Castleman disease
Castleman disease has a few well-recognized types that differ in how many lymph nodes are involved, the speed of symptoms, and the role of certain viruses. Daily life often makes the differences between symptom types clearer. Some people mainly notice swelling in one area, while others feel widespread symptoms like fever, weight loss, and fatigue. Not everyone will experience every type.
Unicentric (UCD)
One lymph node region is enlarged and often causes pressure symptoms nearby. Many feel well otherwise, though fatigue or mild fevers can occur. Surgery to remove the single node often helps.
Multicentric HHV‑8–associated
Several lymph node areas are involved and symptoms are more systemic. Fevers, night sweats, weight loss, and swelling in the legs or belly can flare. This type is linked to the HHV‑8 virus and is more common in people with weakened immunity.
Multicentric iMCD
Multiple regions are affected without evidence of HHV‑8 infection. People often have recurrent fevers, fatigue, anemia, and fluid buildup, and flares can come in waves. Doctors sometimes classify symptoms as inflammatory versus organ-related.
POEMS‑associated variant
This variant occurs with POEMS syndrome, which includes nerve damage, hormone changes, and skin findings. People may notice numbness or weakness in the feet and hands along with enlarged lymph nodes. Treatment usually targets both POEMS and the Castleman process.
TAFRO subtype (iMCD-TAFRO)
This iMCD subtype features thrombocytopenia, kidney trouble, high fevers, fluid around organs, and small or normal-sized lymph nodes. Symptoms can escalate quickly with swelling, fatigue, and shortness of breath. Among the variants of Castleman disease, this one often requires urgent treatment.
What genetics can tell you about symptoms
Certain hereditary changes in immune-regulating genes, like IL6 or mTOR pathway genes, can amplify inflammation, leading to fevers, night sweats, enlarged lymph nodes, and fatigue. These variants may heighten cytokine signals, which drive symptoms more intensely and sometimes more persistently.
Causes and risk factors
Researchers do not fully understand the causes of Castleman disease, and it is not contagious or inherited.
A virus called human herpesvirus 8 (HHV-8) can trigger multicentric disease, especially in people with HIV or a weakened immune system.
Knowing the risks can help you feel more in control.
Risk factors for Castleman disease also include older age for some types, being male in some groups, and medical situations like organ transplant or long-term immune suppression.
Lifestyle steps play a smaller role, but preventing and treating HIV and using immune-suppressing medicines only when needed with your doctor may lower some risk.
Environmental and biological risk factors
Many people want to understand what might raise their chances of Castleman disease. Doctors often group risks into internal (biological) and external (environmental). Knowing these can help you watch for early symptoms of Castleman disease and seek care sooner. Here are the main biological and environmental factors researchers have identified.
Infection with human herpesvirus 8 (HHV-8) is a key environmental driver for some multicentric forms of Castleman disease. Exposure and transmission patterns vary by community and region.
People living with HIV have a higher risk of HHV-8–associated multicentric Castleman disease, especially when the immune system is very weak. This risk relates to reduced immune control over the virus.
Conditions or medicines that suppress the immune system can increase risk. Examples include medicines after an organ transplant or chemotherapy for cancer. Lowered defenses can let HHV-8 reactivate and fuel inflammation.
Risk of multicentric disease rises in older adults, while unicentric Castleman disease can occur at any age. Age itself does not cause it, but immune changes over time may contribute.
Genetic risk factors
Most people with Castleman disease do not have an inherited cause. So far, researchers have not identified confirmed genetic risk factors for Castleman disease that pass through families. Some cases show DNA changes only inside the affected lymph node, but these are acquired and not passed on. Risk is not destiny—it varies widely between individuals.
No inherited cause: There is no proven inherited gene change that causes Castleman disease. Family history usually does not affect risk. Most children of affected parents are not at increased risk.
Family history impact: Having a relative with this condition does not meaningfully raise your personal chance of developing it. Familial cases have been reported only rarely.
Somatic mutations: In some people, affected lymph node cells show acquired genetic changes (somatic mutations). These changes are confined to the node and are not passed to children. No single recurring mutation has been confirmed.
Chromosome changes: Some enlarged nodes show patchy chromosome changes when examined. Findings vary widely between individuals. These are acquired changes rather than inherited ones.
Pathway genes: Researchers are studying genes involved in immune and inflammation pathways relevant to Castleman disease. To date, no specific inherited variant has been tied to higher risk or disease severity. Evidence remains limited and evolving.
Lifestyle risk factors
Castleman disease isn’t caused by lifestyle choices, but daily habits can influence symptoms, treatment tolerance, and overall quality of life. The lifestyle risk factors for Castleman disease are best thought of as behaviors that can worsen fatigue, swelling, and medication side effects or make them easier to manage. Small, consistent changes may help you feel and function better alongside medical treatment.
Eating enough calories and protein helps maintain muscle and strength during flares or treatment. A produce-rich, fiber-forward pattern may support energy and digestion.
Gentle aerobic and resistance exercise can reduce fatigue and preserve stamina. Even short, frequent walks help maintain function during symptom flares or therapy.
Consistent, adequate sleep can ease fatigue and support daytime energy. A regular sleep schedule may also improve pain tolerance and mood stability.
Alcohol can strain the liver and may interact with therapies used in Castleman disease. Limiting or avoiding it can reduce side effects and support recovery.
Risk prevention
Because the exact cause varies, there’s no guaranteed way to prevent Castleman disease. Prevention is about lowering risk, not eliminating it completely. Most steps aim to reduce infections linked to the multicentric form, especially HHV‑8 and HIV, and to find problems early. If you’re at higher risk, steady medical care and avoiding infections can help lower complications.
Use condoms and never share needles to lower chances of HHV‑8 and HIV. This may reduce risk of HHV‑8–associated multicentric Castleman disease.
Get tested regularly if you have risk factors. Effective HIV treatment lowers HHV‑8 activity and the chance of Castleman disease flares.
Routine vaccines like flu and pneumonia shots reduce infection triggers. If you live with Castleman disease or have higher risk, ask about timing and which vaccines are right for you.
Learn early symptoms of Castleman disease, such as ongoing fever, night sweats, swollen glands, and weight loss. Seek medical care quickly if these show up to speed diagnosis and treatment.
Transmission
Castleman disease is not contagious and cannot be passed from one person to another. It is not known to be inherited and does not run in families.
In some people, especially those with weakened immune systems, multicentric Castleman disease is linked to a virus called human herpesvirus 8 (HHV‑8). HHV‑8 can spread through close contact such as saliva, sexual contact, or blood exposure, but most people who acquire HHV‑8 never develop Castleman disease. So while the virus can be transmitted, Castleman disease itself does not “spread” between people.
When to test your genes
Castleman disease is usually not inherited, so most people don’t need genetic testing for diagnosis. Consider testing if your care team suspects a hereditary immune or cancer‑predisposition syndrome, or if you have a strong family history of related blood cancers or unexplained immune problems. Genetic results can guide surveillance, medication choices, and clinical trial options.
Diagnosis
Swollen lymph nodes that don’t settle, low energy, or night sweats often prompt a check-up. Getting a diagnosis is often a turning point toward answers and support. Doctors combine your story, exam findings, imaging, blood work, and a biopsy to confirm Castleman disease and define its type. Understanding how Castleman disease is diagnosed helps guide treatment and follow-up.
Your provider asks about fevers, night sweats, weight changes, and other symptoms and checks for enlarged lymph nodes. They also look for an enlarged spleen or liver and signs of fluid buildup or skin changes.
A complete blood count can show anemia or low platelets, and inflammatory markers may be elevated. Kidney and liver tests help assess organ strain and overall health.
CT or PET-CT maps which lymph nodes are enlarged and whether one area or many are involved. These images help distinguish unicentric from multicentric patterns and guide where to biopsy.
Removing all or part of a lymph node is the key step to confirm Castleman disease. A full surgical (excisional) biopsy often provides the clearest answer and helps rule out lymphoma.
Stages of Castleman disease
Castleman disease does not have defined progression stages. This is because it behaves differently depending on whether it’s localized to a single lymph node area (unicentric) or involves several areas with whole‑body symptoms (multicentric), so it doesn’t follow a predictable step‑by‑step course. Different tests may be suggested to help confirm the type and rule out other causes like infections or lymphoma, and doctors consider early symptoms of Castleman disease alongside scans and blood work. Diagnosis usually requires a lymph node biopsy, and monitoring often includes periodic imaging, lab markers of inflammation, and checking how you’re feeling over time.
Outlook and prognosis
Day to day, the outlook with Castleman disease depends on the type and how quickly treatment starts. Some people have a single enlarged lymph node removed and feel well afterward; others manage ongoing fatigue, night sweats, or swelling that affects work or sleep. Everyone’s journey looks a little different. When thinking about the future, it helps to know that targeted medicines, antiviral strategies when appropriate, and modern cancer-style therapies have improved survival and quality of life over the past decade.
Doctors call this the prognosis—a medical word for likely outcomes. Unicentric Castleman disease (one area of lymph nodes) usually has an excellent outlook after surgery, with very low mortality and rare relapses, though periodic follow-up is still important. Multicentric Castleman disease (many areas) varies: people without other immune challenges often do well with newer treatments, but those with uncontrolled inflammation or severe infections face higher risks, especially early on. Many people ask, “What does this mean for my future?”, and the honest answer is that early symptoms of Castleman disease—like unexplained fevers, weight loss, or swelling—should prompt timely care because faster control of inflammation is linked to better long-term health.
With ongoing care, many people maintain regular routines, work, and family life, though flares can happen and may need treatment adjustments. Understanding the prognosis can guide planning and help you and your team watch for relapse signs, manage complications like anemia or nerve pain, and reduce infection risk. Talk with your doctor about what your personal outlook might look like, including how your specific subtype, lab patterns, and response to therapy shape risk over the next few years.
Long-term effects
Castleman disease can have a quiet stretch, then a flare that brings symptoms back, so planning ahead matters. Long-term effects vary widely, depending on whether disease is in one area (unicentric) or affects many areas (multicentric). Early symptoms of Castleman disease can be vague—fatigue, low-grade fever, or swollen glands—and some long-term issues mirror those same themes over time. Many do well after surgery for unicentric disease, while multicentric disease often needs ongoing treatment and monitoring to prevent complications.
Many people feel low energy that comes and goes. It can limit work, exercise, and social plans. Good days may alternate with tiring days.
Lymph nodes may stay enlarged or swell during flares. This can feel tender or cause a sense of fullness in the neck, armpit, belly, or groin. Doctors may track changes over years to see patterns.
The spleen or liver can stay enlarged in Castleman disease. This may cause pressure under the ribs or early fullness when eating. Your care team may monitor size with scans over time.
Ongoing inflammation can lead to anemia. This can cause shortness of breath, headaches, or pale skin. Some also have low platelets or white cells during active disease.
How is it to live with Castleman disease?
Living with Castleman disease often means pacing your energy and planning around unpredictable waves of fatigue, night sweats, and swollen lymph nodes that can flare and settle without much warning. Many find themselves juggling frequent medical visits, blood tests, and imaging alongside work, school, and family life, with infections hitting harder and taking longer to shake. The condition can strain routines for partners, children, and close friends too, as plans may change last minute and caregiving or extra support becomes part of the week. With a clear care plan, vaccinations kept up to date, and honest communication about limits and needs, people can protect their health and keep relationships steady even when symptoms ebb and flow.
Treatment and drugs
Treatment for Castleman disease depends on the type (unicentric or multicentric), how active the disease is, and your overall health. For unicentric Castleman disease, surgery to remove the single enlarged lymph node is often curative; if surgery isn’t possible, focused radiation or medicines that shrink lymph tissue may be used. Multicentric Castleman disease usually needs medicines that calm the overactive immune signaling, such as monoclonal antibodies targeting interleukin-6, sometimes combined with steroids, antiviral therapy if human herpesvirus-8 is involved, and, in selected cases, chemotherapy or immunomodulating drugs. Not every treatment works the same way for every person, so doctors closely track symptoms, lab tests, and scans to adjust the plan and manage side effects. Ask your doctor about the best starting point for you, including whether clinical trials or specialized centers might offer additional options.
Non-drug treatment
Living with Castleman disease can affect energy, sleep, and daily routines, even between treatments. Alongside medicines, non-drug therapies can ease symptoms, protect overall health, and help you stay active. Options may vary depending on whether you have unicentric or multicentric disease and how your body is doing right now. The aim is to manage fatigue, pain, and swelling; lower infection risk; and support nutrition, movement, and emotional well‑being.
Removing a single enlarged lymph node can relieve pressure and improve symptoms in unicentric disease. This procedure is often curative for localized cases.
Targeted radiation can shrink a node that cannot be safely removed with surgery. It may reduce pain, pressure, or early symptoms of Castleman disease such as fatigue or night sweats.
If you feel well and your tests are stable, your team may monitor closely without immediate treatment. Regular check-ins help catch changes early and avoid overtreatment.
A dietitian can help you maintain weight, protein, and micronutrients when appetite is low. Small, frequent meals and adequate fluids support energy and healing.
Your genes may have an impact on how drugs work for you
Some medicines for Castleman disease work better or cause more side effects depending on gene differences that affect immune signaling and how your body processes drugs. Pharmacogenetic testing can sometimes guide dosing or drug choice, though decisions still rely on clinical response.
Pharmacological treatments
Medicines for Castleman disease aim to calm the overactive immune signals driving inflammation, shrink enlarged lymph nodes, and prevent organ damage. Options depend on the subtype (unicentric vs. multicentric), virus status (HHV‑8, HIV), and how active the disease is. Not everyone responds to the same medication in the same way. Your team may combine medicines or adjust dosing over time to balance benefits and side effects.
Siltuximab (Sylvant) targets interleukin‑6 directly, while tocilizumab (Actemra) blocks the IL‑6 receptor. These drugs can reduce fevers, night sweats, anemia, and node size, especially in idiopathic multicentric Castleman disease. They may improve energy and other early symptoms of Castleman disease.
Rituximab targets CD20 on B cells to quiet the immune overactivity. It’s commonly used for HHV‑8–associated multicentric Castleman disease and when IL‑6 blockers aren’t suitable. Doctors may pair it with steroids or chemotherapy for stronger control.
Prednisone and similar steroids can quickly ease inflammation, fevers, and swelling. They are often used short term for symptom control or as a bridge while other treatments take effect. Doses are tapered to limit side effects.
For HHV‑8–associated disease, ganciclovir or valganciclovir may be used to suppress the virus. Effective antiretroviral therapy for people living with HIV is also crucial to stabilize the immune system. These medicines are often given alongside rituximab.
Genetic influences
It’s natural to ask whether family history plays a role. For most people with Castleman disease, it does not seem to be inherited, and having several relatives affected is rare. Researchers haven’t identified a single gene that causes Castleman disease or consistently raises risk. In some cases, doctors may find gene changes only within the affected lymph node tissue—acquired over time—rather than in all the cells of the body, which means they aren’t passed down. When Castleman disease is linked to HHV-8 (a herpes virus), especially in those with weakened immunity, the illness is driven by the infection rather than by inherited genes. Because of this, genetic testing isn’t routinely used to diagnose or predict early symptoms of Castleman disease, though it may be considered in research studies or to rule out related conditions.
Is Castleman disease genetic?
Genetics play a limited role in Castleman disease; most cases are not inherited. Variations in immune-related genes may influence risk or how active the disease becomes. In some subtypes, viruses like HHV‑8, not inherited variants, drive the condition.
Pharmacogenetics—how genetics influence drug effects
Even though Castleman disease isn’t usually inherited, your genes can still influence how you respond to some treatments. Differences in drug‑processing genes may change how quickly you break down steroids, cyclosporine, or chemotherapy used in certain cases, which can shift both side effects and benefit. Genetic testing can sometimes identify how your body handles certain medicines, but it isn’t routinely required for Castleman disease care and doctors mainly guide therapy by the disease subtype and whether a virus called HHV‑8 is present. There’s no standard pharmacogenetic test to predict response to anti‑IL‑6 medicines, though researchers continue to study why some people need higher or lower doses. This falls under pharmacogenetics, a growing field that links your genes with how medicines work in your body. These genetic differences don’t change early symptoms of Castleman disease, but they can influence which drugs feel effective for you and how closely your team monitors for side effects. If side effects are unexpected or severe, your clinician may adjust the dose, review other medicines for interactions, or consider targeted testing to better tailor treatment.
Interactions with other conditions
Infections and other illnesses can change how symptoms show up or flare, especially in those with the multicentric form; for example, an active virus or even a bad cold can intensify swollen nodes, fevers, and fatigue. Doctors call it a “comorbidity” when two conditions occur together, and this matters because HIV and the related HHV‑8 virus are closely linked to one subtype of multicentric Castleman disease and can also be tied to Kaposi sarcoma. There’s also a higher-than-average risk of certain lymphomas, so new night sweats, weight loss, or rapidly enlarging nodes deserve prompt attention. Some people have overlap with POEMS syndrome or autoimmune conditions such as lupus or rheumatoid arthritis, which can make early symptoms of Castleman disease look similar to a flare of those disorders. Treatments can interact too: steroids, immunomodulators, monoclonal antibodies, and antivirals may affect each other or raise infection risk, and drug combinations used for HIV or hepatitis need careful coordination. Because these links can look different from person to person, it helps to share full medication lists and other diagnoses at every visit when managing Castleman disease alongside another condition.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described unexplained swellings in the neck, armpit, or chest that waxed and waned, sometimes with fevers and fatigue, and sometimes with few symptoms at all. Families and communities once noticed patterns—an otherwise healthy young adult slowed by night sweats and weight loss, or a chest X-ray during military service revealing an unexpected mass. These scattered stories foreshadowed what we now group as Castleman disease.
First described in the medical literature as a peculiar lymph node growth in the 1950s, early reports came from chest surgeons who found enlarged nodes around the lungs that looked tumor-like but weren’t cancer. Initially understood only through symptoms, later pathology studies showed a characteristic overgrowth pattern inside the nodes. As more cases emerged, clinicians recognized at least two broad presentations: a single cluster of enlarged nodes in one area and a form that affected multiple regions with whole‑body inflammation.
In recent decades, awareness has grown that Castleman disease is not one single condition but a group of related disorders sharing similar lymph node changes. Researchers linked some cases—especially in people with weakened immune systems—to human herpesvirus‑8 (HHV‑8). Around the same time, studies highlighted a key role for inflammatory signals like interleukin‑6, which helped explain fevers, anemia, and the “flu‑like” feeling many experience. These insights shifted thinking from “mysterious mass” to a problem of the immune system stuck in overdrive.
Building on this early work, scientists refined categories that are now used worldwide: unicentric Castleman disease, where one area is involved; multicentric Castleman disease, where many areas are active; and HHV‑8–associated forms. A subset of multicentric cases occurs without HHV‑8, often called idiopathic, and international registries and collaborative studies have shaped modern diagnostic criteria. Imaging advances, safer biopsy techniques, and standardized lab testing made it easier to tell Castleman disease apart from infections, autoimmune conditions, and cancers that can look similar.
Treatment history reflects this evolving understanding. Surgery was once the mainstay for single‑area disease and remains curative for many. For multicentric Castleman disease, care moved from broad immune‑suppressing medicines and chemotherapy toward targeted approaches that calm specific inflammatory pathways, improving survival and quality of life. The discovery of HHV‑8’s role led to antiviral strategies and tailored therapies in affected groups.
From early theories to modern research, the story of Castleman disease shows how careful observation, pathology, and immunology can come together to reframe a rare condition. The journey continues through international networks that collect patient experiences and tissue samples, helping to fine‑tune definitions and guide new treatments. Knowing the condition’s history helps explain why getting the right diagnosis may take time—and why today’s care is more precise than ever.